Keep your expectations in check.

Dec 10 (Reuters) - Pfizer will cut over 200 jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg ...

After beefing up the target of its global cost-savings drive once again, Pfizer is continuing to see its plan through with ...

With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Dec ...

Pfizer has entered into a global collaboration and license agreement with YaoPharma for the development, manufacturing and commercialization of YP05002, a small-molecule GLP-1 receptor agonist ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the ...

Dec 9 (Reuters) - Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of ...

Pfizer’s RIF and severance practices face scrutiny in a Dec. 8 New Jersey filing by a former physician challenging OWBPA ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.

Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.